Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,194,272
  • Shares Outstanding, K 63,189
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,500 K
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.72
  • Number of Estimates 1
  • High Estimate -0.72
  • Low Estimate -0.72
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -67.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.18 +5.94%
on 04/17/19
20.89 -7.80%
on 04/03/19
-0.10 (-0.52%)
since 03/25/19
3-Month
12.51 +53.96%
on 01/29/19
20.89 -7.80%
on 04/03/19
+5.61 (+41.10%)
since 01/25/19
52-Week
11.45 +68.21%
on 10/24/18
26.13 -26.29%
on 05/04/18
-3.09 (-13.83%)
since 04/25/18

Most Recent Stories

More News
Consolidated Research: 2019 Summary Expectations for Wyndham Hotels & Resorts, Apellis Pharmaceuticals, Transcat, Emerald Expositions Events, Capitala Finance, and Seres Therapeutics -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Wyndham Hotels & Resorts Inc. (NYSE:WH),...

WH : 53.91 (-0.75%)
MCRB : 6.93 (+1.17%)
TRNS : 24.38 (+0.16%)
CPTA : 8.51 (-0.99%)
APLS : 19.26 (+1.90%)
EEX : 14.00 (+1.16%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 19.26 (+1.90%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 19.26 (+1.90%)
Florida Poly Unveils Plans for State-of-the-Art Research Building

Florida Polytechnic University announced plans to build another iconic building on its campus that will serve as a research hub for the Central Florida region, becoming a magnet for high-tech development...

APLS : 19.26 (+1.90%)
U.S. Army Awards ARA Contract for Its Cutting-Edge Augmented Reality Software

The U.S. Army awarded Applied Research Associates, Inc. (ARA) a sole-source contract in January to integrate its patent-protected state-of-the-art Augmented Reality software (ARC4: Augmented Reality, Command,...

APLS : 19.26 (+1.90%)
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 19.26 (+1.90%)
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 19.26 (+1.90%)
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 19.26 (+1.90%)
Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy

No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process

APLS : 19.26 (+1.90%)
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals(R) for APL-2 in Hematologic Indications

Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement

APLS : 19.26 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade APLS with:

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the...

See More

Key Turning Points

2nd Resistance Point 19.95
1st Resistance Point 19.60
Last Price 19.26
1st Support Level 18.76
2nd Support Level 18.27

See More

52-Week High 26.13
Fibonacci 61.8% 20.52
Last Price 19.26
Fibonacci 50% 18.79
Fibonacci 38.2% 17.06
52-Week Low 11.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar